Abstract

A COMPREHENSIVE ANALYSIS OF THE CARDIOVASCULAR BENEFITS OF DAPAGLIFLOZIN

V. J. Dawn*, V. R. Irene, Elsa Maria John, O. O. Megha, Sajeev Suresh and K. S. Shanimol

ABSTRACT

Diabetes mellitus (DM) is a collection of metabolic disorders marked by persistently high blood sugar levels brought on by deficiencies in the secretion of insulin, its action, or both. The t wo most common types of diabetes are type 1 and type 2. There are several ways to diagnose diabetes, including the HbA1C test. Tests for glucose tolerance, blood sugar fasting, and blood sugar randomness. People with diabetes are prescribed anti-diabetic drugs to help manage and stabilize their blood glucose levels. Because of its significant benefits for the cardiovascular system, the sodium-glucose co- transporter 2 (SGLT2) inhibitor dapagliflozin has become a key therapeutic drug in the treatment of type 2 diabetic mellitus (T2DM). According to clinical trials and real-world investigations dapagliflozin dramatically lowers the risk of major adverse cardiovascular events (MACE), heart failure-related hospitalization, and the advancement of renal illness. These mainly occurs by the mechanisms like enhanced diuresis, natriuresis,
decreased arterial stiffness, and favorable effects on blood pressure and weight, are not dependent on glucose control. The study also emphasizes the good safety profile of dapagliflozin, which supports its use in the treatment of type 2 diabetes, particularly in patients with high cardiovascular risk. Dapagliflozin has the potential to revolutionize the treatment of type 2 diabetes by improving cardiovascular outcomes in addition to glucose management. The significance dapagliflozin plays in promoting all-encompassing diabetic management and enhancing patient prognosis is highlighted in this review.

Keywords: Dapagliflozin, Major adverse cardiovascular events(MACE), Sodium-glucose co- transporter 2(SGLT2), Diabetes.